FUJIFILM Corp. engages in the provision of imaging and information solutions. Its offers photography equipment, supplies and services, optical devices, healthcare, high-performance materials, graphic systems, recording media, and industrial products. The company was founded on October 2, 2006 and is headquartered in Tokyo, Japan.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Versitech Ltd. is a Hong Kong Chinese company located in Hong Kong and ultimately controlled by the Government of Hong Kong Special Administrative Region. The firm provides business services.

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Jilin Aodong Taonan Pharmaceutical Co., Ltd., established on 1998-02-06, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Class III medical device business;Pharmaceutical commissioned production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Annoroad Gene Technology (Beijing) Co., Ltd., established on 2012-04-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;Software outsourcing service;Digital Technology Services;Conference and Exhibition Services;Labor service(Does not include labor dispatch);Financial Advisory;business management;Asset management services for self-owned capital investment;Computer System Services;Retailing of computer software, hardware and auxiliary equipment;Machinery sales;Instrument sales;Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);Hardware retail;Office Equipment Sales;Electrical Equipment Sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Rubber Products Sales;Sales of daily glass products;Sales of plastic products;Sales of daily-use ceramic products;Sales of special ceramic products;Sales of architectural ceramic products;Machinery and Equipment Leasing;electronic,Mechanical equipment maintenance(No special equipment);Import and export;Technology Import and Export;Import and export agency;Production of Class I Medical Devices;Medical Research and Experimental Development;Health Consulting Services(Does not include medical services).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Production of Class III Medical Devices;Inspection and testing service;Construction Engineering Construction;medical service;Production of Class II Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. Its products include cytological diagnostic, immunohistochemical diagnostic, and molecular diagnostic reagents and instruments. The company was founded by Xiang Ting Cai on July 6, 2005 and is headquartered in Guangzhou, China.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Fuzhou Aidikang Medical Laboratory Co., Ltd., established on 2009-02-06, Business scope includes licensed projects:medical service;Import and export;Technology Import and Export;road freight transport(Does not contain dangerous goods)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Sales of Class I Medical Devices;software development;software sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Information system integration service;Wholesale of computer software, hardware and auxiliary equipment;Retailing of computer software, hardware and auxiliary equipment;Socioeconomic Advisory Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Beijing Blue Spectrum Biotechnology Development Co., Ltd., established on 2013-09-25, Business scope includes technology development,Technology Promotion,technical consulting,Technical Services;Rental of construction machinery and equipment;Sales of chemical products(Free of Hazardous Chemicals),Equipment,I,IIclass of medical devices,Instrumentation;Technology Import and Export;Sales No.IIIclass of medical devices.(The medical device business license is valid until2024year5moon27day).(Enterprises independently choose operating projects according to law,Projects subject to approval in accordance with the law to carry out business activities,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Intas is among the top-10 Indian pharmaceutical companies and the largest privately held pharmaceutical company in India, with annual turnover in excess of US$ 1 billion, of which 60% comes from international operations. The group has an extensive geographic footprint with presence in 70 countries worldwide and more than 80% of export revenue coming from US, UK and EU. Intas operates over 10 manufacturing facilities worldwide. These facilities have regulatory approvals from multiple global agencies and enjoy an excellent reputation for quality and compliance. The group has capabilities to produce a wide variety of dosage forms including solid orals, liquids, lyophilized sterile preparations, creams, drops and injectables. Intas employs 12,000 people globally with over 400 located in Europe. The company employs over 800 scientists; spends approximately 6% of sales on R&D per annum and has been granted 27 international patents. In addition to generics formulation, R&D is focused on value added products such as biosimilars, value added and improved generics using novel drug delivery systems (NDDS) and innovative active pharmaceutical ingredients (API). Intas has the largest commercialised portfolio of biosimilars in India and is the first Indian pharmaceutical company to launch a biosimilar in the EU. Intas is privately held, based in Ahmedabad India, and backed by two leading financial investors, Temasek and ChrysCapital

The European Institute of Oncology strives to achieve the excellence in the area of cancer prevention, early diagnosis and effective treatment through the development of clinical and scientific research and through organizational and managerial innovation, with a constant focus on the quality of the service provided to the patients. At the Institute, all the physicians work full time on an exclusive basis. In this way, doctors avoid dividing their time between hospital and private practice and dedicate all of their time to treatment, research, continuing professional education and interdisciplinary exchanges with their colleagues within the same facility to the benefit of their patients.

SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470—DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation. SuperGen, Inc. was founded in 1991.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

Shandong Keshuo Biotechnology Co., Ltd., established on 2008-10-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Wholesale of computer software, hardware and auxiliary equipment;Office Equipment Sales;Instrument sales;Sales of office equipment consumables;Experimental analysis instrument sales;Office Supplies Sales;Sales of plastic products;Sales of technical glass products;Medical equipment rental(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)